These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38060243)

  • 1. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
    Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
    Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
    J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.
    Tan G; Jin B; Qian X; Wang Y; Zhang G; Agyekum EA; Wang F; Shi L; Zhang Y; Mao Z; Shi C; Xu Y; Li X; Zhang L; Li S
    Sci Rep; 2024 Oct; 14(1):23719. PubMed ID: 39390090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Stratification Using a Novel Genetic Classifier Including
    Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
    Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
    Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
    Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
    Mu Z; Zhang X; Liang D; Fang J; Chen G; Guo W; Sun D; Sun Y; Kai Z; Huang L; Liang J; Lin Y
    Chin J Cancer Res; 2024 Feb; 36(1):25-35. PubMed ID: 38455372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
    Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower
    Meng Z; Matsuse M; Saenko V; Yamashita S; Ren P; Zheng X; Jia Q; Tan J; Li N; Zheng W; Zhao L; Mitsutake N
    IUBMB Life; 2019 Jul; 71(7):1030-1040. PubMed ID: 31026111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
    Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
    Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
    Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
    Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of BRAF
    Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
    Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
    Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
    J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
    Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
    Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
    Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
    Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.